Abstract
Hypomyelinating leukodystrophy (HLD) is a rare genetic heterogeneous disease affecting myelin development in the central nervous system. This study investigates a family with HLD-7 caused by a POLR3A mutation. The proband and her brothers exhibited progressive neurological decline, dentin dysplasia, and hypogonadotropic hypogonadism. Genetic analysis identified a homozygous POLR3A mutation (c.2300G>T, p.Cys767Phe). Functional assays revealed that while the mutation leads to increased protein expression, it impairs RNA Polymerase III transcriptional activity, particularly affecting 5S rRNA, tRNAs, and Myelin Basic Protein (MBP) expression.
Introduction
Hypomyelinating leukodystrophy-7 (HLD-7) is a subtype of HLD linked to mutations in the POLR3A gene, which encodes the largest subunit of RNA Polymerase III (Pol III). Pol III is responsible for transcribing essential small non-coding RNAs, such as tRNAs and 5S rRNA, which are critical for protein synthesis and cellular maintenance. Mutations in this complex disrupt myelin production, leading to white matter atrophy and diverse clinical symptoms including ataxia, cognitive decline, and dental abnormalities.
Methods
The study combined clinical evaluation with molecular genetics. Brain MRI and neurological exams characterized the phenotype. Whole-exome sequencing (WES) identified the candidate variant, followed by Sanger sequencing for family segregation. Functional impacts were assessed in HeLa cells transfected with wild-type (WT) or mutant (p.Cys767Phe) POLR3A plasmids. Protein levels were measured via Western Blot, and transcriptional activity was quantified using RT-qPCR for Pol III targets like 5S rRNA, BC200, and tRNA Leu-CAA.
Key Results
The proband (IV6) presented with cognitive decline, dentin dysplasia, and hormonal imbalances. Her brothers (IV1, IV2, and IV4) showed varying degrees of ataxia and dystonia. MRI scans revealed significant white matter atrophy and thinning of the corpus callosum across affected family members.
Genetic testing identified a homozygous missense mutation, c.2300G>T (p.Cys767Phe), in exon 17 of POLR3A. The consanguineous parents were heterozygous carriers. Structural modeling suggested that the p.Cys767Phe substitution disrupts critical hydrogen bonds, likely destabilizing the Pol III complex.
Functional Analysis: The Compensation Paradox
Functional assays revealed a "compensation paradox." Cells expressing the mutant POLR3A showed higher protein levels than those with the wild-type protein, suggesting a cellular attempt to compensate for defective machinery or reduced protein turnover. However, this increased protein did not translate to increased function. Instead, Pol III transcriptional activity was significantly impaired. Levels of 5S rRNA, BC200, and tRNA Leu-CAA were lower in mutant cells compared to wild-type. Crucially, the expression of Myelin Basic Protein (MBP) was also reduced, providing a direct link between the genetic defect and the physical degradation of white matter observed clinically.
Discussion and Conclusion
This study highlights the complex molecular pathology of HLD-7. The p.Cys767Phe mutation in POLR3A causes a functional deficit in RNA Polymerase III despite an overabundance of the mutant protein. This "transcriptional frustration" leads to a shortage of essential non-coding RNAs and myelin-related proteins, ultimately causing the progressive neurological and developmental symptoms seen in the affected family. The findings underscore the importance of functional validation in understanding how specific variants drive rare genetic leukodystrophies.
Summary updated